Aster DM Healthcare LtdQ1 FY26Healthcare Services

Aster DM Healthcare Ltd

Q1 FY26 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→QCIL expects continued strong growth momentum in both revenue and margins for the next two years, supported by about 900 additional beds being added in this period.
→Mature hospitals show steady growth (~13.5-14% revenue growth YoY) with EBITDA expansion driven by complexity enhancement and oncology volume growth.
→Emerging and focused units report robust ramp-ups: emerging units grew 62.4% YoY in revenue; focused units grew 21% YoY with improved EBITDA margins.
→Patient volumes are rising with IP volumes up 7-10% yearly and OP footfalls growing similarly, driving revenue increases.
→Expansion plans include adding beds in Raipur, Bhubaneswar, Banjara, Nagercoil (+100 beds), Nampally (+28 beds), Malakpet, Chattogram, Vizag, and Indore (greenfield).
→Continued focus on clinical talent attraction and specialty capability upgrades to enhance case mix and ARPOB (average revenue per occupied bed).
→Growth driven by increasing oncology, cardiology, robotic procedures, and international patient inflows.
→Payor mix favorably shifting towards cash + insurance segments, supporting higher revenue per patient.

Margin guidance

Category 3

→Q4 FY26 showed strong growth with revenue up 18% YoY and EBITDA up 23% YoY; full-year EBITDA grew 24.1% YoY, crossing INR 1,000 crores for the first time.
→EBITDA margin expanded by 103 bps in Q4 and 136 bps for the year, demonstrating improving operating leverage and cost efficiencies.
→Mature units grew revenue by 13.5% and EBITDA by 20.7%, with EBITDA margin at 33.2%, while emerging units grew revenue 62.4% and improved EBITDA margin to 17.9%, signaling strong growth runway.
→Management expects continued revenue growth (~16-17% top-line seen in FY26) and margin expansion (~1-1.5% margin expansion observed) over the next two years, driven by capacity additions, synergy realization, and clinical talent strengthening.
→Expansion plans include adding ~2,500 beds over the coming years, boosting capacity to 8,150 beds, balancing greenfield and brownfield investments for return-driven capital deployment.
→Focus and emerging units showing strong EBITDA growth potential support improving overall profitability and EPS growth in medium term.

3 more insights locked — sign up free to unlock

Fundraise plans

- As of FY26, Aster DM Healthcare reported a moderate gross debt of INR 701 crores and a robust liquidity position with cash and cash equivalents of INR 1,327 crores. - The company has planned capital expenditure of INR 2,700 crores over the next 3-4 years to support growth, with INR 350 crores already invested by March 2026. - There is no explicit mention in the transcript of any current or future plans for fundraising through new debt or equity issuance. - The management emphasized maintaining disciplined capital allocation and sustainable profitability, implying cautious and planned capital deployment. - If any fundraising plans arise, the company indicated they would be communicated separately, as seen by their offer to share certain financial details offline. Therefore, based on available information, there is no announced new fundraising through debt or equity at this time.

Order book

→QCIL has an expansion budget of around INR 2,000 crores for approximately 1,700 beds.
→Out of these, around 1,500 beds are planned as brownfield projects.
→The blended per bed capex is approximately INR 1-1.1 crores.
→Greenfield per bed capex is higher, around INR 1.5-1.6 crores, while brownfield is in the range of INR 0.8-1.1 crores.
→For Aster DM Healthcare, over the next four years, there is a plan to add about 2,500 beds at a cost of INR 2,700 crores.
→INR 350 crores has already been invested up to March 2026, with the remaining amount to be deployed over the next 3–4 years.
→Recent expansions include operationalizing Whitefield Block D with 159 beds and Aster Ramesh Sanghamitra Ongole with 75 beds in April 2026.

Capex plans

Yes

→For FY26, capital expenditure was INR 549 crores, with 45% towards expansion projects.
→Operationalized:
→ - Whitefield Block D with 159 beds (April 2026).
→ - Aster Ramesh Sanghamitra Ongole brownfield expansion with 75 beds (April 2026).
→Plans to add ~2,500 beds over the next 4 years at a cost of INR 2,700 crores; INR 350 crores invested till March 2026.
→QCIL expansion budget is around INR 2,000 crores for 1,700 beds (1,500 brownfield, 200 greenfield).
→Per bed capex:
→ - Brownfield: INR 0.8-1.1 crores.
→ - Greenfield: INR 1.5-1.6 crores.
→Focus on sprucing up existing assets, adding clinical capabilities, and enhancing oncology services (e.g., Banjara).
→Addition of 900 beds planned over next two years.
→Expansion and capability enhancement in clusters like Raipur, Bhubaneswar, Banjara, Hyderabad, Nagercoil, and Indore.

How does Aster DM Healthcare Ltd rank vs peers in Healthcare Services?

Pro feature

1Aster DM Healthcare Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Unlock with Pro

Want more stocks like Aster DM Healthcare Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio